Bamco Inc. NY Has $135.69 Million Stake in argenx SE (NASDAQ:ARGX)

Bamco Inc. NY decreased its position in argenx SE (NASDAQ:ARGX - Free Report) by 4.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 250,304 shares of the company's stock after selling 11,174 shares during the quarter. Bamco Inc. NY owned approximately 0.42% of argenx worth $135,685,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ARGX. Blue Trust Inc. grew its position in shares of argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company's stock worth $28,000 after purchasing an additional 62 shares in the last quarter. J.Safra Asset Management Corp boosted its stake in shares of argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock valued at $30,000 after purchasing an additional 59 shares during the period. GAMMA Investing LLC grew its stake in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after acquiring an additional 40 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in argenx during the 2nd quarter worth $76,000. Finally, Cromwell Holdings LLC increased its stake in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after buying an additional 66 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on ARGX shares. Barclays upgraded argenx from an "equal weight" rating to an "overweight" rating in a report on Tuesday, August 6th. Wolfe Research upgraded argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 target price on the stock in a research note on Tuesday, November 12th. Scotiabank raised shares of argenx from a "sector perform" rating to a "sector outperform" rating and increased their target price for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Oppenheimer reissued an "outperform" rating and issued a $675.00 price target (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. Finally, JPMorgan Chase & Co. lifted their target price on shares of argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a research note on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $630.42.

argenx Trading Up 0.3 %

NASDAQ ARGX traded up $2.15 during trading on Monday, reaching $618.70. The company's stock had a trading volume of 158,645 shares, compared to its average volume of 309,802. The stock has a market capitalization of $37.35 billion, a PE ratio of -700.63 and a beta of 0.61. argenx SE has a 1-year low of $327.73 and a 1-year high of $622.32. The business has a 50-day moving average price of $565.73 and a 200-day moving average price of $498.07.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter last year, the company earned ($1.25) EPS. As a group, analysts expect that argenx SE will post 2.2 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.